Search

The article outlines the significance of the Award for Excellence in Human Research Protection in the U.S. It was launched in 2001 with the aim of encouraging, recognizing and rewarding excellence and innovation in human research protection on individual investigators, institutions and research sponsors. The recognition is also intended to facilitate improvements and openness in human research. INSET: Blueprint for Excellence.

Reports on the challenges faced by clinicians in drafting a project plan for clinical trials. Benefits of implementing a performance metrics system in all operational departments; Efficacy of performance metrics in tracking the efficiency of the cooperation with study sites and contract research organizations; Maintenance of sophisticated systems for research and development timeline, cost, and productivity tracking based on the input from research-based pharmaceutical firms.

The article focuses on performance metrics for biopharmaceutical companies that work with clinical research organizations (CROs) in conducting studies in the U.S. According to the study by Health Industry Insights and sponsored by Paraxel, the metrics help project accurate finishing times and assist in keeping within a budget. The study found that CROs are developing stronger relationships with their outsourcing partners to provide expertise on a global scale.

This article presents information about the pharmaceutical company Covance Inc. The company has its headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies. The company's annual revenue exceeds $1 billion. The company has global operation in 18 countries and has over 7,000 employees worldwide. The company is driven by a commitment to scientific, operational and service excellence. They help sponsors accomplish all of their drug development goals.

Discusses the objective of modernizing techniques for drug development in the Critical Path Initiative. Need for the collaborative research effort to create performance standards and predictive tools; Requirement of scientific and regulatory creativity and risk-taking to redesign the drug development paradigm; Plans to revamp drug development processes and tools.